SCHEMBL32669609

SCHEMBL32669609

CN(CC#Cc1ccccc1Cl)C(=O)/C(C#N)=C(\O)c1ccc(O)c([N+](=O)[O-])c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 6/20 0.47
COMT P21964 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 2/20 0.36
MITF O75030 1/20 0.36
S1PR4 O95977 1/20 0.36
S1PR1 P21453 1/20 0.36
MAPT P10636 3/20 0.36
KMT2A Q03164 3/20 0.36
VCAM1 P19320 1/20 0.35
MEN1 O00255 2/20 0.35
NPC1 O15118 1/20 0.35
MAPK1 P28482 1/20 0.35
AURKB Q96GD4 1/20 0.34
DPP4 P27487 1/20 0.34
PREP P48147 1/20 0.34
DPP9 Q86TI2 1/20 0.34
CTSB P07858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32669955 0.90 FTO (0.60) FTOCOMTALDH1A1LMNAMAPT
SCHEMBL32669920 0.90 FTO (0.52) FTOCOMTSMN1; SMN2ALDH1A1LMNA
SCHEMBL32669980 0.88 FTO (0.52) FTOCOMTSMN1; SMN2ALDH1A1LMNA
SCHEMBL32669657 0.88 FTO (0.50) FTOCOMTSMN1; SMN2ALDH1A1LMNA
SCHEMBL32669651 0.86 FTO (0.48) FTOCOMTSMN1; SMN2ALDH1A1LMNA
SCHEMBL32670128 0.82 FTO (0.61) FTOCOMTALDH1A1LMNAMAPT
SCHEMBL32669862 0.81 FTO (0.60) FTOCOMTALDH1A1LMNAMAPT
SCHEMBL32669522 0.81 FTO (0.59) FTOCOMTALDH1A1LMNAMAPT
SCHEMBL32669728 0.81 FTO (0.59) FTOCOMTALDH1A1LMNAMAPT
SCHEMBL32669634 0.79 SLC22A12 (0.38) FTOCOMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035341-A1 FTO INHIBITORS RPXDS CO LTD (CN) 2026-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035341-A1 FTO INHIBITORS FTO, LDLR, GPR119 FTO 1/4885COMT 52/4885SMN1; SMN2 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.